A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Last updated:
2026-08-22
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 1/2A, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF BMS-986507 (BL-B01D1) COMBINATIONS IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.

Intervention/treatment:
BMS-986507 / PEMBROLIZUMAB / OSIMERTINIB / OPDIVO
Medical condition:
ADVANCED SOLID TUMORS
Protocol code:
CA244-0001
Control number:
291527
Status:
Recruiting
Approved:
November 29, 2024
Trial phase:
Phase 1, Phase 2
For more information:
ClinicalTrials.gov - NCT06618287
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

Alberta

Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Recruiting
Name
Quincy Chu, Site 0024
Role
CONTACT
Phone:
7804328248

Ontario

Local Institution - 0023
Ottawa, Ontario, K1H 8L6
WITHDRAWN
Local Institution - 0064
Newmarket, Ontario, L3Y 2P9
Not yet recruiting
Name
Site 0064
Role
CONTACT
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6
Recruiting
Name
Scott Laurie, Site 0026
Role
CONTACT
Phone:
6137377700

Quebec

Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 3E4
Recruiting
Name
Marie Florescu, Site 0022
Role
CONTACT
Phone:
5148908000
Jewish General Hospital
Montreal, Quebec, H3T 1E2
Recruiting
Name
Jennifer Friedmann, Site 0025
Role
CONTACT
Phone:
514340822224915
Local Institution - 0144
Montreal, Quebec, H4A3J1
Not yet recruiting
Name
Site 0144
Role
CONTACT
Did you find what you were looking for?